Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | BCL2 | P10415 | 7/20 | 0.47 |
| ▸ | BAK1 | Q16611 | 3/20 | 0.47 |
| ▸ | HRH1 | P35367 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | BCL2L1 | Q07817 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL219876 | 0.89 | HRH1 (0.59) | HTR7HRH3BCL2BAK1HRH1 | |
| Hydrochloric Acid SCHEMBL219199 | 0.88 | HRH1 (0.60) | HTR7HRH3BCL2BAK1HRH1 | |
| SCHEMBL1569359 | 0.88 | HTR7 (0.50) | HTR7HRH3BCL2BAK1HRH1 | |
| Hydrochloric Acid SCHEMBL5686168 | 0.88 | HRH1 (0.60) | HTR7HRH3BCL2BAK1HRH1 | |
| SCHEMBL2058761 | 0.87 | HRH1 (0.57) | HTR7HRH3BCL2BAK1HRH1 | |
| Hydrochloric Acid SCHEMBL10930701 | 0.86 | HRH1 (0.58) | HTR7HRH3BCL2BAK1HRH1 | |
| SCHEMBL7628259 | 0.86 | HTR7 (0.48) | HTR7HRH3BCL2BAK1HRH1 | |
| SCHEMBL5182319 | 0.86 | HTR7 (0.53) | HTR7HRH3BCL2BAK1HRH1 | |
| Hydrochloric Acid SCHEMBL10930120 | 0.85 | HTR7 (0.47) | HTR7HRH3BCL2BAK1HRH1 | |
| SCHEMBL1446951 | 0.84 | HTR7 (0.57) | HTR7HRH3BCL2BAK1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6469009-B1 | MIXTURE CONSISTING ESSENTIALLY OF PSEUDOEPHEDRINE AND COMPOUND SELECTED FROM 2-(4-(DIPHENYLMETHYL)-1-PIPERAZINYL)-ACETIC ACID OR AMIDE DERIVATIVES, THEIR INDIVIDUAL OPTICAL ISOMERS OR PHARMACEUTICALLY ACCEPTABLE SALTS | UCB, S.A. (BE) | 2002-10-22 | — | — | US | claimed |
| US-20010020023-A1 | Pharmaceutical compositions for the treatment of rhinitis | UCB PHARMA, S.A. (BE) | 2001-09-06 | — | — | US | claimed |
| US-4525358-A | ANTIHISTAMINES, ANTIALLERGENS, ANTISPASMODICS, BRONCHODILATORS | UCB PHARMACEUTICALS, INC. (US) | 1985-06-25 | — | — | US | claimed |
| US-7968549-B2 | Diarylmethylpiperazines as therapeutic agents for viral myocarditis | MATSUMORI AKIRA | 2011-06-28 | — | — | US | disclosed |
| US-20070281947-A1 | Diarylmethylpiperazines As Prophylactic Or Therapeutic Agents For Viral Myocarditis | UCB FARCHIM SA (CH) | 2007-12-06 | — | — | US | disclosed |
| EP-1521581-A1 | DIARYLMETHYLPIPERAZINES AS PROPHYLACTIC OR THERAPEUTIC AGENTS FOR VIRAL MYOCARDITIS | UCB Farchim S.A. (CH) | 2005-04-13 | — | — | EP | disclosed |
| US-20050026890-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease | EPIGENESIS PHARMACEUTICALS LLC | 2005-02-03 | — | — | US | disclosed |
| US-20040156859-A1 | GP-41 peptides, BBB peptides, anticancer agents, antihistamines, bronchodilators, hypotensive agents, antiangina agents, opioids, analgesics, antidepressants, and hypothyroid agents reactive with amino, hydroxyl or thiol groups | CONJUCHEM, INC. (CA) | 2004-08-12 | — | — | US | disclosed |
| US-6706892-B1 | ADMINSTERING MALEIMIDE DERIVATIVE TO COVALENTLY BOND PROTEIN; WOUND HEALING, ANTIBIOTIC, ANTIINFLAMMATORY, ANTICARCINOGENIC, HYPOTENSIVE, AND ANALGESIC AGENTS | CONJUCHEM, INC. (CA) | 2004-03-16 | — | — | US | disclosed |
| WO-2004004728-A1 | DIARYLMETHYLPIPERAZINES AS PROPHYLACTIC OR THERAPEUTIC AGENTS FOR VIRAL MYOCARDITIS | UCB FARCHIM S.A. (CH) | 2004-01-15 | — | — | WO | disclosed |
| EP-1235618-A2 | BIOCONJUGATION IN VIVO TO PULMONARY OR BLOOD COMPONENTS | Conjuchem, Inc. (CA) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001017568-A2 | BIOCONJUGATION IN VIVO TO PULMONARY OR BLOOD COMPONENTS | CONJUCHEM, INC. (CA) | 2001-03-15 | — | — | WO | disclosed |
| EP-1014983-A1 | NAPROXEN/CETIRIZINE COMPOSITIONS AND METHODS FOR TREATING RESPIRATORY DISORDERS | THE PROCTER & GAMBLE COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999015173-A1 | COMPOSITIONS AND METHODS FOR TREATING RESPIRATORY DISORDERS | THE PROCTER & GAMBLE COMPANY (US) | 1999-04-01 | — | — | WO | disclosed |
| US-4525358-A | ANTIHISTAMINES, ANTIALLERGENS, ANTISPASMODICS, BRONCHODILATORS | UCB PHARMACEUTICALS, INC. (US) | 1985-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281947-A1 | Diarylmethylpiperazines As Prophylactic Or Therapeutic Agents For Viral Myocarditis | ACE2, TNNT2, MYLK2 | HTR7 2862/4885HRH3 1605/4885BCL2 297/4885 |
| US-20050026890-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease | KIT, HSD11B2, HSD3B1 | HTR7 277/4885HRH3 29/4885BCL2 4851/4885 |
| US-20040156859-A1 | GP-41 peptides, BBB peptides, anticancer agents, antihistamines, bronchodilators, hypotensive agents, antiangina agents, opioids, analgesics, antidepressants, and hypothyroid agents reactive with amino, hydroxyl or thiol groups | OGFR, HDGF, SERPINA6 | HTR7 794/4885HRH3 175/4885BCL2 1446/4885 |
| US-20010020023-A1 | Pharmaceutical compositions for the treatment of rhinitis | HRH4, HRH2, HRH1 | HTR7 45/4885HRH3 4/4885BCL2 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.